Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer

por Niu, Huifeng, Manfredi, Mark, Ecsedy, Jeffrey A.
Publicado 2015

Patient Enrichment for Precision‐Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials

por Dalton, William S., Sullivan, Daniel, Ecsedy, Jeffrey, Caligiuri, Michael A.
Publicado 2018

Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib

por Wang, Lihong, Arras, Janet, Katsha, Ahmed, Hamdan, Saif, Belkhiri, Abbes, Ecsedy, Jeffrey, El‐Rifai, Wael
Publicado 2017

Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines

por Liu, Ningbo, Wang, Yong Antican, Sun, Yunguang, Ecsedy, Jeffrey, Sun, Jifeng, Li, Xue, Wang, Ping
Publicado 2019

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

por Kelly, Kevin R, Ecsedy, Jeffrey, Medina, Ernest, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Nawrocki, Steffan T, Giles, Francis J, Carew, Jennifer S
Publicado 2011

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

por Kelly, Kevin R., Shea, Thomas C., Goy, André, Berdeja, Jesus G., Reeder, Craig B., McDonagh, Kevin T., Zhou, Xiaofei, Danaee, Hadi, Liu, Hua, Ecsedy, Jeffrey A., Niu, Huifeng, Benaim, Ely, Padmanabhan Iyer, Swaminathan
Publicado 2013

Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation

por Currier, Mark A., Sprague, Les, Rizvi, Tilat A., Nartker, Brooke, Chen, Chun-Yu, Wang, Pin-Yi, Hutzen, Brian J., Franczek, Meghan R., Patel, Ami V., Chaney, Katherine E., Streby, Keri A., Ecsedy, Jeffrey A., Conner, Joe, Ratner, Nancy, Cripe, Timothy P.
Publicado 2017

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models

por Davis, S. Lindsey, Robertson, Kelli M., Pitts, Todd M., Tentler, John J., Bradshaw-Pierce, Erica L., Klauck, Peter J., Bagby, Stacey M., Hyatt, Stephanie L., Selby, Heather M., Spreafico, Anna, Ecsedy, Jeffrey A., Arcaroli, John J., Messersmith, Wells A., Tan, Aik Choon, Eckhardt, S. Gail
Publicado 2015

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A...

por Niu, Huifeng, Shin, Hyunjin, Gao, Feng, Zhang, Jacob, Bahamon, Brittany, Danaee, Hadi, Melichar, Bohuslav, Schilder, Russell J., Coleman, Robert L., Falchook, Gerald, Adenis, Antoine, Behbakht, Kian, DeMichele, Angela, Dees, Elizabeth Claire, Perez, Kimberly, Matulonis, Ursula, Sawrycki, Piotr, Huebner, Dirk, Ecsedy, Jeffrey
Publicado 2017

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

por Carol, Hernan, Boehm, Ingrid, Reynolds, C. Patrick, Kang, Min H., Maris, John M., Morton, Christopher L., Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Wu, Jianrong, Wozniak, Amy E., Yang, Yu, Manfredi, Mark, Ecsedy, Jeffrey, Wang, Jianmin, Neale, Geoffrey, Houghton, Peter J., Smith, Malcolm A., Lock, Richard B.
Publicado 2011

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

por Sells, Todd B., Chau, Ryan, Ecsedy, Jeffrey A., Gershman, Rachel E., Hoar, Kara, Huck, Jessica, Janowick, David A., Kadambi, Vivek J., LeRoy, Patrick J., Stirling, Matthew, Stroud, Stephen G., Vos, Tricia J., Weatherhead, Gabriel S., Wysong, Deborah R., Zhang, Mengkun, Balani, Suresh K., Bolen, Joseph B., Manfredi, Mark G., Claiborne, Christopher F.
Publicado 2015